Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker CYTK · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Eje… NCT06736574 · Heart Failure, Heart Failure With Reduced Ejection Fraction Omecamtiv Mecarbil (OM), Placebo | CYTK Cytokinetics | Phase 3 | Recruiting | 1,800 | Sep 2027 | Registry ↗ |
| Oct 13, 2026 | Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults… NCT04848506 · Symptomatic Hypertrophic Cardiomyopathy (HCM) Aficamten (5 - 20 mg) | CYTK Cytokinetics | Phase 2/3 | Enrolling by invitation | 900 | Mar 2029 | Registry ↗ |
| Sep 22, 2026 | A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptom… NCT06081894 · Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy Aficamten, Placebo | CYTK Cytokinetics | Phase 3 | Active, not recruiting | 500 | Aug 31, 2026 | Registry ↗ |
| Aug 27, 2026 | AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerabil… NCT06793371 · Symptomatic Heart Failure With Preserved Ejection Fraction… CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to… | CYTK Cytokinetics | Phase 2 | Recruiting | 60 | Sep 2026 | Registry ↗ |
| Aug 18, 2026 | A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hype… NCT06412666 · Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopa… Aficamten, Placebo | CYTK Cytokinetics | Phase 2/3 | Active, not recruiting | 65 | Jan 2030 | Registry ↗ |
| Jun 9, 2026 | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in… NCT05767346 · Obstructive Hypertrophic Cardiomyopathy (oHCM) Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Plac… | CYTK Cytokinetics | Phase 3 | Completed | 175 | Feb 28, 2025 | Registry ↗ |
| Mar 3, 2026 | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With S… NCT05186818 · Obstructive Hypertrophic Cardiomyopathy (oHCM) Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match… | CYTK Cytokinetics | Phase 3 | Completed | 282 | Nov 10, 2023 | Registry ↗ |
| Feb 24, 2026 | Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of… NCT04219826 · Hypertrophic Cardiomyopathy (HCM) CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg) | CYTK Cytokinetics | Phase 2 | Completed | 96 | Feb 28, 2023 | Registry ↗ |
| May 1, 2025 | A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants NCT05877053 · Healthy Participants CK-4021586, Placebo for CK-4021586 | CYTK Cytokinetics | Phase 1 | Completed | 102 | Nov 20, 2024 | Registry ↗ |
| Mar 30, 2025 | Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults NCT04175808 · QT Intervals Changes, QTc Intervals Changes Omecamtiv Mecarbil (OM), Placebo | CYTK Cytokinetics | Phase 1 | Completed | 70 | Mar 4, 2020 | Registry ↗ |
| Jan 24, 2025 | A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects NCT03767855 · Symptomatic Obstructive Hypertrophic Cardiomyopathy, Health… CK-3773274 - Granules in Capsule, Placebo - Granules in Cap… | CYTK Cytokinetics | Phase 1 | Completed | 114 | Jan 3, 2020 | Registry ↗ |
| Dec 5, 2024 | A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Scl… NCT04944784 · Amyotrophic Lateral Sclerosis Reldesemtiv, Placebo | CYTK Cytokinetics | Phase 3 | Terminated | 489 | Jul 18, 2023 | Registry ↗ |
| Oct 17, 2024 | A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants NCT05662215 · Healthy Participants CK-3828136, Placebo for CK-3828136 | CYTK Cytokinetics | Phase 1 | Terminated | 57 | Aug 8, 2023 | Registry ↗ |
| Aug 13, 2024 | A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) NCT05442775 · Amyotrophic Lateral Sclerosis Reldesemtiv | CYTK Cytokinetics | Phase 3 | Terminated | 71 | Jun 7, 2023 | Registry ↗ |
| Dec 19, 2023 | Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval NCT05924815 · Healthy Participants Aficamten, Aficamten-matching Placebo | CYTK Cytokinetics | Phase 1 | Completed | 44 | Nov 14, 2023 | Registry ↗ |
| Mar 7, 2023 | Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure NCT03759392 · Heart Failure With Reduced Ejection Fraction Omecamtiv Mecarbil, Placebo | CYTK Cytokinetics | Phase 3 | Completed | 276 | Nov 8, 2021 | Registry ↗ |
| Nov 5, 2021 | Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced… NCT02929329 · Heart Failure Omecamtiv Mecarbil, Placebo | CYTK Cytokinetics | Phase 3 | Completed | 8,256 | Sep 14, 2020 | Registry ↗ |
| Aug 12, 2021 | COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure NCT01786512 · Modified Release Oral Formulation, Left Ventricular Systoli… Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbi… | CYTK Cytokinetics | Phase 2 | Completed | 544 | Jul 22, 2015 | Registry ↗ |
| Jul 30, 2021 | Omecamtiv Mecarbil Post-trial Access Study NCT04464525 · Chronic Heart Failure With Reduced Ejection Fraction Omecamtiv mecarbil | CYTK Cytokinetics | Phase 3 | Withdrawn | 0 | Nov 27, 2026 | Registry ↗ |
| Jul 30, 2021 | Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal In… NCT01737866 · Heart Failure AMG 423 | CYTK Cytokinetics | Phase 1 | Completed | 13 | Jan 2013 | Registry ↗ |
| Jul 30, 2021 | Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients NCT01077167 · Heart Failure Omecamtiv mecarbil | CYTK Cytokinetics | Phase 2 | Withdrawn | 0 | May 2011 | Registry ↗ |
| Jul 27, 2021 | Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced… NCT02695420 · Heart Failure With Reduced Ejection Fraction 25 mg Omecamtiv Mecarbil, Placebo | CYTK Cytokinetics | Phase 2 | Completed | 81 | Apr 6, 2017 | Registry ↗ |
| Jul 27, 2021 | Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults NCT02601001 · Healthy Volunteer Omecamtiv mecarbil, Placebo | CYTK Cytokinetics | Phase 1 | Completed | 50 | Jan 6, 2016 | Registry ↗ |
| Jul 27, 2021 | Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subje… NCT01300013 · Heart Failure Placebo, Omecamtiv mecarbil | CYTK Cytokinetics | Phase 2 | Completed | 614 | Apr 2013 | Registry ↗ |
| Jun 15, 2021 | A Study for Patients Who Completed VITALITY-ALS (CY 4031) NCT02936635 · Amyotrophic Lateral Sclerosis (ALS) tirasemtiv | CYTK Cytokinetics | Phase 3 | Completed | 280 | Oct 26, 2018 | Registry ↗ |
| May 14, 2021 | A Study of CK-1827452 Infusion in Stable Heart Failure NCT00624442 · Heart Failure CK-1827452, CK-1827452 | CYTK Cytokinetics | Phase 2 | Completed | 45 | Feb 2009 | Registry ↗ |
| Sep 11, 2020 | A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic La… NCT03160898 · Amyotrophic Lateral Sclerosis Reldesemtiv, Placebo | CYTK Cytokinetics | Phase 2 | Completed | 458 | Mar 7, 2019 | Registry ↗ |
| Sep 9, 2020 | Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for… NCT02496767 · Amyotrophic Lateral Sclerosis Tirasemtiv, Placebo tablets | CYTK Cytokinetics | Phase 3 | Completed | 744 | Mar 9, 2017 | Registry ↗ |
| Aug 31, 2020 | A Study of CK-2127107 in Patients With Spinal Muscular Atrophy NCT02644668 · Spinal Muscular Atrophy Placebo, Reldesemtiv 150 mg | CYTK Cytokinetics | Phase 2 | Completed | 70 | May 31, 2018 | Registry ↗ |
| Mar 31, 2020 | Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) NCT01709149 · Amyotrophic Lateral Sclerosis CK-2017357, Placebo tablets | CYTK Cytokinetics | Phase 2 | Completed | 711 | Mar 2014 | Registry ↗ |
| Jan 21, 2020 | Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency NCT00748579 · Heart Failure CK-1827452, CK-1827452 | CYTK Cytokinetics | Phase 2 | Terminated | 2 | Nov 2008 | Registry ↗ |
| Jan 13, 2020 | A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma NCT00343564 · Non-Hodgkin's Lymphoma, Hodgkin's Disease SB-743921, SB-743921 | CYTK Cytokinetics | Phase 1/2 | Completed | 68 | Jul 2010 | Registry ↗ |
| Sep 24, 2019 | Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis NCT01268280 · Myasthenia Gravis Placebo, 250 mg CK-2017357 | CYTK Cytokinetics | Phase 2 | Terminated | 32 | Oct 2012 | Registry ↗ |
| May 14, 2019 | A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication NCT01131013 · Intermittent Claudication, Peripheral Artery Disease Placebo, 375 mg CK-2017357 | CYTK Cytokinetics | Phase 2 | Completed | 61 | Mar 2011 | Registry ↗ |
| May 10, 2019 | A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) NCT01089010 · Amyotrophic Lateral Sclerosis Placebo, 250 mg CK-2017357 | CYTK Cytokinetics | Phase 2 | Completed | 67 | Nov 2010 | Registry ↗ |
| May 7, 2019 | A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Latera… NCT01378676 · Amyotrophic Lateral Sclerosis Placebo (Part A), CK-2017357 (Part A) | CYTK Cytokinetics | Phase 2 | Completed | 49 | Mar 2012 | Registry ↗ |
| May 6, 2019 | A Study of Ispinesib in Metastatic Breast Cancer NCT00607841 · Breast Neoplasms Ispinesib, Ispinesib | CYTK Cytokinetics | Phase 1 | Terminated | 16 | Nov 2009 | Registry ↗ |
| May 3, 2019 | Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral… NCT01486849 · Amyotrophic Lateral Sclerosis CK-2017357, Placebo | CYTK Cytokinetics | Phase 2 | Completed | 27 | Mar 2012 | Registry ↗ |
| Aug 21, 2018 | PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina NCT00682565 · Heart Failure, Myocardial Ischemia CK-1827452 24mg and 6 mg iv infusion, CK-1827452 12.5mg cap… | CYTK Cytokinetics | Phase 2 | Completed | 94 | Nov 2008 | Registry ↗ |
| Oct 14, 2015 | A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers NCT01380223 · Heart Failure placebo, omecamtiv mecarbil | CYTK Cytokinetics | Phase 1 | Completed | 35 | Apr 2006 | Registry ↗ |
40 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:34 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances